key: cord-0924315-vjy31exn
authors: Finsterer, Josef
title: SARS-CoV-2 associated Miller-Fisher syndrome or polyneuritis cranialis
date: 2021-06-11
journal: Environ Sci Pollut Res Int
DOI: 10.1007/s11356-021-14797-3
sha: dc826c346aa4610088803be364110ff284b112f7
doc_id: 924315
cord_uid: vjy31exn

nan

Full recovery was achieved in 6 patients, partial recovery in 6 patients, and one patient died (Table 1 ). This review showed that the outcome of SARS-CoV-2-associated MFS/PNC is fair and that not only cranial nerves III, IV, and VI supplying the extra-ocular eye muscles can be affected in MFS but also other cranial nerves and also the peripheral nerves.

Concerning the methods of the study, it is unclear why PubMed was searched for appropriate hits only at a single day and not repeatedly. Searching the database only once can be associated with overlooking appropriate articles. Furthermore, application of only "MFS" as a search term is insufficient given the fact that MSF may be overlapping with other subtypes of GBS. Additional helpful search terms could be "ophthalmoparesis", "polyneuritis cranialis", "ptosis", or "oculomotor nerve palsy".

It is mentioned that COVID-19 was diagnosed in five of the seven patients prior to onset of MFS, suggesting that the diagnosis of COVID-19 in the two remaining patients was established after onset of MFS. If MFS developed before COVID-19 in two patients, it is conceivable that MFS in these two patients was not causally related to COVID-19 but may have another etiology. The statement that the temporal relationship between MFS and COVID-19 was not reported in three patients does not comply with the information that COVID-19 was diagnosed before/after onset of MFS in 5/2 patients.

A further shortcoming is that anti-GQ1b antibodies were detected in only a single patient. The fact that not all MFS patients were tested positive GQ1b is interesting as GQ1b antibodies are reported positive in up to 100% of the cases (Teener 2012) . A further limitation is that the 7 cases included in the review were not referenced.

Responsible Editor: Philippe Garrigues * Josef Finsterer fifigs1@yahoo.de

Overall, the review is appealing but has several limitations which should be accomplished before drawing conclusions as those presented.

Author contribution JF: design, literature search, discussion, first draft, critical comments

Ethics approval The study was approved by the institutional review board.

Informed consent Informed consent was obtained.

The author declares no competing interest.

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Guillain-Barre syndrome in 220 patients with COVID-19

COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: the experience of Liguria region in Italy

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2

Miller Fisher syndrome in the COVID-19 era -a novel target antigen calls for novel treatment

COVID-19-Associated Miller Fisher syndrome: MRI findings

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Atypical variant of Guillain Barre syndrome in a Patient with COVID-19

Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2

Table 1 SARS-CoV-2-associated MFS reported as per the end of

Miller Fisher syndrome and COVID-19: is there a link?

Miller-Fisher syndrome after SARS-CoV-2 infection

Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement

Miller Fisher's syndrome

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations